PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400736
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400736
The global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market is poised for substantial expansion, with global revenues reaching approximately US$ 23.3 billion in 2024. The market is expected to reach a valuation of approximately US$ 47 billion by the end of 2031.
ADHD is a neurobiological behavioral disorder that affects individuals across various age groups, including children, adolescents, and adults. It is characterized by difficulties in focus, hyperactivity, and impulsivity, often attributed to an imbalance in the neurotransmitters dopamine and noradrenaline in the brain. Common medications for ADHD include psychostimulants like methylphenidate and amphetamines, as well as non-psychostimulants like atomoxetine.
ADHD is a significant public health concern worldwide, with a high incidence rate, affecting approximately 5-10% of adolescents and children. While most research focuses on children aged 7 to 17, it is essential to note that adults can also have ADHD. The disorder poses significant challenges to academic, interpersonal, and professional performance.
"Establishment of Adjuvant Therapies"
While drug therapy is the primary treatment for ADHD, there is a rising interest in non-pharmaceutical treatments, such as behavioral therapy and digital therapy (DTx), to complement drug therapy.
"Side-Effects and Limitations of Current Therapies"
Pharmacological therapies for ADHD may have side effects, including insomnia, lack of appetite, or nausea. Additionally, behavioral interventions have limitations, and children with ADHD often do not exhibit normalized behavioral function with behavior therapy alone.
The U.S. market for ADHD therapeutics is witnessing growth due to the rising incidence of adults with ADHD and the expansion of the biopharmaceutical industry.
Germany is becoming an attractive market for ADHD therapeutics, with an increasing focus on the underdiagnosed cases of ADHD in adults.
China is emerging as a significant player in the global ADHD therapeutics market, with growing investments in ADHD research and the presence of regional market players.
Key companies in the industry are focused on developing novel ADHD drugs and expanding their market shares through mergers, acquisitions, and outsourcing production to reduce costs.
Market Segmentation
Amphetamine
Methylphenidate
Dextroamphetamine
Dexmethylphenidate
Lisdexamfetamine Dimesylate
Atomoxetine
Bupropion
Guanfacine
Clonidine